Clinical Trial Update: Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MDX-1100, an anti-CXCL10 monoclonal antibody, in combination with methotrexate for active rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MDX-1100
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED